Valuation: GI Dynamics, Inc.

Market Cap 440K 382K 358K 326K 613K 42.01M 623K 4.21M 1.64M 21.04M 1.65M 1.62M 70.14M P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 3.28M 2.84M 2.66M 2.43M 4.57M 313M 4.64M 31.31M 12.24M 157M 12.31M 12.05M 522M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 2025-08-04
Director of Finance/CFO 57 2025-07-31
Chief Tech/Sci/R&D Officer - 2023-03-31
Director TitleAgeSince
Director/Board Member - 2020-10-19
Director/Board Member - -
Director/Board Member 69 2023-09-30
Date Insider Type Main position Quantity % Market Cap.
1/28/21 Free

Chairman

1,384,483 0.4875%
1/28/21 Free

Chief Executive Officer

11,075,869 3.8998%

Financials

2019 2020
Net sales - -
Net income -17.33M -15.02M -14.07M -12.83M -24.13M -1.65B -24.5M -165M -64.69M -828M -65.08M -63.66M -2.76B -11.14M -9.65M -9.04M -8.25M -15.5M -1.06B -15.74M -106M -41.56M -532M -41.81M -40.9M -1.77B
Net Debt 2.89M 2.5M 2.34M 2.14M 4.02M 275M 4.08M 27.56M 10.77M 138M 10.84M 10.6M 460M 2.84M 2.46M 2.3M 2.1M 3.95M 271M 4.01M 27.11M 10.6M 136M 10.66M 10.43M 452M
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. GIDYL Stock